Other institutions, including MSKCC, NCI, and FHCRC, also have conducted initial clinical trials to evaluate autologous CD19-targeted CAR-T cells for R/R CLL. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.